Skip to main content

Table 2 The distribution of individual IL-13 promoter genotypes in the clinical groups

From: Interleukin (IL)-13 promoter polymorphisms (-7402 T/G and -4729G/A) condition susceptibility to pediatric severe malarial anemia but not circulating IL-13 levels

Genotypes Hemoglobin Levels (g/dL) P value n (%) Non-SMA (Hb ≥ 6.0 g/dL) n (%) SMA (Hb < 6.0 g/dL) n (%) P value
IL-13 -7402 T > G
TT 6.4 (3.0) 0.744b 334 (86.3) 194 (87.4) 140(84.8) 0.767a
TG 6.1 (3.0) 49 (12.7) 26 (11.7) 23 (13.9)
GG 6.2 (2.0) 4 (1.0) 2 (0.9) 2 (1.2)
IL-13 -4729 A > G
GG 6.4 (4.0) 0.521b 205(53.0) 78 (47.3) 127 (57.2) 0.152a
GA 6.0 (3.0) 131 (33.9) 63 (38.2) 68 (30.6)
AA 6.2 (3.0)   51 (13.2) 24 (14.5) 27 (12.2)  
  1. Data are presented as [n, (8722%)] for proportions of IL-13 promoter variants -7402 T > G and -4729 G > A within the SMA (n = 165) and non-SMA (n = 222) groups based on age- and geographically-matched Hb concentrations in children in western Kenya (Hb < 6.0 g/dL, with any density parasitemia) [35]. aChi-square analysis. The Hb levels are presented as medians (IQR), and bKruskal Wallis test was used to compare the levels between the genotypes.